# of Displayed Technologies: 30 / 34

Applied Category Filter (Click To Remove): Therapeutics


Categories

Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
  • College: College of Medicine (COM)
  • Inventors: Li, Zihai
  • Licensing Officer: He, Panqing

An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
  • College: College of Medicine (COM)
  • Inventors: Bansal, Shyam; Gumina, Richard
  • Licensing Officer: He, Panqing

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
  • College: College of Medicine (COM)
  • Inventors: Ranganathan, Parvathi; Garzon, Ramiro
  • Licensing Officer: He, Panqing

Therapeutic uses of the scavenging protein cocktail to treat plasma protein imbalances or depletion
TS-053103 — Uncontrolled hemolysis (i.e., destruction of red blood cells) is characterized by the increase of circulating toxic cell-free hemoglobin, heme and iron in the bloodstream. In vivo, the body’s natural supply of plasma scavenger proteins acts to neutralize these toxic species. However, these scavenger proteins such as haptoglobin, hemopexin and transferrin, which detoxify hemoglobin, heme and iron, respectively, are depleted in various clinical conditions such as hemorrhagic shock, burns, surgery, organ transplantation, sepsis and trauma. Dr. Andre Palmer’s lab at The Ohio State University has developed a novel therapeutic protein mixture, which can be used to treat plasma protein imbalances or depletion caused by the adverse events described above. The properties of this protein mixture are beneficial as they lend themselves to an inexpensive manufacturing process and potential improvements in clinical outcomes.
Fluid replacement as part of resuscitation efforts in clinical care is a cornerstone of treatment especially in cases with severe trauma. The regular usage of these fluids in hospitals requires the mixture to be easily transported, easily stored and applicable across a wide variety of patients. To…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Davis, Stewart

Activation of human Argonaute3 (AGO3) using cityRNAs
TS-051298 — MicroRNAs (miRNAs) are small non-coding RNAs that control gene expression post-transcriptionally. Their sequences differ, but their lengths fall within a range of ~20-23 nucleotides because the precursor miRNAs are processed by Dicer. Dicer cleaves long double-stranded RNA (dsRNA) molecules into s…
  • College: College of Arts & Sciences
  • Inventors: Nakanishi, Kotaro; Park, Mi Seul
  • Licensing Officer: Willson, Christopher

Novel acellular vaccine for protection against Bordetella infection
TS-050524 — Despite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis (wP) vaccines in the 1940s and acellular pertussis (aP) vaccines in 1990s reduced mortality due to pertussis. Des…
  • College: College of Medicine (COM)
  • Inventors: Deora, Rajendar; Mishra, Meenu; Sukumar, Neelima
  • Licensing Officer: Schworer, Adam

Mini-PCDH15 for treatment of deafness
TS-050433 — A gene therapy solution for Usher Syndrome Type 1F.
Mutations in PCDH15 cause Usher 1F, a recessive syndrome characterized by profound congenital deafness and absence of vestibular function, and progressive blindness beginning in the second decade. Because patients who lack hearing and balance rely on vision for communication and mobility, the late…
  • College: College of Arts & Sciences
  • Inventors: Sotomayor, Marcos
  • Licensing Officer: Willson, Christopher

Apoprotein manufacturing and methods for protein purification
TS-050238 — Methods of purifying proteins that can be used in various applications such as drug delivery, bioimaging and hemolysis treatment.
Novel protein and apoprotein purification strategies are valuable tools with a wide variety of medical and research applications. While there are existing techniques for protein and apoprotein purification, some of these have flaws such as the use of harsh denaturants, highly flammable solvents, l…
  • College: College of Engineering (COE)
  • Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
  • Licensing Officer: Davis, Stewart

Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
  • College: College of Pharmacy
  • Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
  • Licensing Officer: He, Panqing

Targeting circular PCMTD1 in leukemias with p53 mutations
TS-049827 — circPCMTD1 is a novel target in p53 mutated leukemias.
Despite recent progress in understanding acute myeloid leukemia (AML) biology and the use of intensive treatments, the long-term overall survival of non-pediatric AML patients is only 30-40% in young patients (<60 years) and less than 10% in elderly AML patients (>60 years). This highlights …
  • College: College of Medicine (COM)
  • Inventors: Garzon, Ramiro; Papaioannou, Dimitrios
  • Licensing Officer: He, Panqing

Inhibition of DGAT for the treatment of cancer
TS-049730 — Dysregulated fat metabolism is an established hallmark of cancer cells. However, the disruption of lipid homeostasis in cancer cells remains an elusive target for therapy. Tumor cells acquire abundant fats for rapid cell growth, but how they avoid toxicity from such loading is unknown. An answer t…
  • College: College of Medicine (COM)
  • Inventors: Guo, Deliang
  • Licensing Officer: He, Panqing

An improved base editor (iABE-NG) for correcting genetic diseases such as Duchenne muscular dystrophy
TS-049505 — An engineered base editor (iABE-NG) that uses an SpCas9 variant, a shortened adenine deaminase domain with eliminated RNA off-target activity, and an intein split for packaging into an adeno-associated virus (AAV), resulting in gene mutation correction.
There are thousands of monogenic diseases that are lacking effective therapeutic treatments. The main bottleneck in developing effective treatment is the ability to effectively edit gene while controlling for the myriad of off-target effects that come with targeting the genome. Duchenne Muscular D…
  • College: College of Medicine (COM)
  • Inventors: Han, Renzhi; Gao, Yandi; Xu, Li
  • Licensing Officer: Davis, Stewart

A Novel Vaccine for Listeriosis Infection
TS-049471 — Listeriosis is an infectious disease caused by the bacterial pathogen Listeria monocytogenes. Although the average number of cases is moderate in the United States (1600-2500/year), listeriosis is a significant health concern due to its exceptionally high fatality rate. Indeed, listeriosis is the …
  • College: OSU Wexner Medical Center
  • Inventors: Seveau, Stephanie
  • Licensing Officer: He, Panqing

Novel epipolythiodioxopiperazine alkaloid natural product derivatives for the treatment of cancer and other diseases
TS-047118 — Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
  • College: College of Pharmacy
  • Inventors: Fuchs, James; Huntsman, Andrew
  • Licensing Officer: He, Panqing

Electrophiles for Re-activation of Aged Acetylcholine Esterase
TS-044619 — Organophosphorus (OP) poisons including sarin, VX, and novichoks are lethal agents of chemical warfare. Their toxicity is due to their direct inhibition of acetylcholinesterase (AChE), an enzyme that is vital to the nervous system via regulation of the neurotransmitter acetylcholine (ACh). AChE in…
  • College: College of Arts & Sciences
  • Inventors: Hadad, Christopher; Callam, Christopher; Corrigan, Thomas; Dicken, Rachel; Dogan Ekici, Ozlem; Fitzpatrick, Keegan; Franjesevic, Andrew; McElroy, Craig; McKenney, Ryan; Muthukrishnan, Siva; Sanan, Toby; Vyas, Shubham; Yoder, Ryan; Young, Amneh "Amneh"
  • Licensing Officer: Willson, Christopher

Live vaccine candidate for Chagas disease
TS-044084 — Trypanosoma cruzi is a protozoan parasite that causes Chagas disease, a PRV-eligible disease that is the leading cause of heart failure in Latin America. Due to migration of infected hosts from endemic regions, Chagas disease is also a growing public health concern in the USA and other migrant des…
  • College: College of Medicine (COM)
  • Inventors: McGwire, Bradford
  • Licensing Officer: He, Panqing

Multi-Functional Drug Delivery Nanodevice for Precision Medicine
TS-041485 — A functionalized DNA nanostructure made through a scaffolded DNA origami molecular self-assembly process to deliver clinically significant concentrations of therapeutics.
This novel therapeutic approach leverages structural nanotechnology to create a DNA nanostructure that acts as a customizable delivery vehicle for therapeutic molecules. The technology allows for a highly tunable and customizable multi-functional drug delivery platform that incorporates interchang…
  • College: College of Engineering (COE)
  • Inventors: Castro, Carlos; Byrd, John; Halley, Patrick; Lucas, Christopher
  • Licensing Officer: He, Panqing

Method to improve efficiency and specificity of human tumor targeting and elimination by using a combination of split & splice protein toxins and oncolytic viruses
TS-040838 — Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.
In combating malignancies as complex as cancer, researchers and clinicians have created a diverse set of strategies to reduce tumor burden. Oncolytic viruses (OVs) have emerged as a promising means of treating this disease due to their potential to selectively target and effectively kill cancer ce…
  • College: College of Arts & Sciences
  • Inventors: Kudryashov, Dmitri; Cripe, Timothy; Kudryashova, Elena; Purde, Vedud
  • Licensing Officer: Willson, Christopher

Treatment of Multiple Sclerosis with Small Molecule IL-6/STAT3 Inhibitors
TS-038701 — Small-molecule prodrugs that target IL-6/STAT3 signaling pathway.
Multiple Sclerosis (MS), an unpredictable and disabling autoimmune disease affecting the central nervous system, is the leading cause of non-traumatic neurological disability in young adults. There have been important advances in MS therapy, such as drugs that slow the progression of the disease a…
  • College: College of Medicine (COM)
  • Inventors: Yang, Yuhong; Li, Chenglong; Racke, Michael
  • Licensing Officer: He, Panqing

A novel synthetic immunomodulator and an adjuvant for vaccines
TS-038032 — A natural plant product possessing potent immunomodulatory activity, which primes T cell immune responses, and could be used for vaccine development.
While vaccines are commonly used today for a variety of diseases and have proven efficacious for disease prevention, some vaccines do not efficiently activate an immune response. Adjuvants can be included in a given vaccine to potentiate immune activation and improve the quality of the vaccine. Th…
  • College: College of Medicine (COM)
  • Inventors: Satoskar, Abhay; Ainslie, Kristy; Bachelder, Eric; Fuchs, James; Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Parinandi, Narasimham
  • Licensing Officer: Davis, Stewart

Targeted molecules for the treatment of cancer
TS-038027 — Novel dihdroorotate dehydrogenase (DHODH) small-molecule inhibitors for the treatment of Acute Myeloid Leukemia, Multiple Myeloma, & Graft vs. Host Disease / Leukemia.
DHODH is a rate-limiting enzyme in de novo pyrimidine synthesis. Rapidly dividing cancer cells are therefore sensitive to blockade of this pathway. New research has shown DHODH inhibition can induce differentiation in acute myeloid leukemia (AML) cell lines, translating to increased survival in an…
  • College: College of Medicine (COM)
  • Inventors: Byrd, John; Abdulrahim, Mouad; Elgamal, Ola; Goodwin, Thomas; Hertlein, Erin; Ravikumar, Pratheepa; Shah, Dimple
  • Licensing Officer: Davis, Stewart

Six Degrees-of-Freedom Quality Assurance Phantom for Radiation Therapy Linear Accelerators
TS-037968 — The medical physics group in the Department of Radiation Oncology has devised a 6DoF phantom that is the first of its kind to fully integrate multiple routine QA tests specifically for a six degrees-of-freedom linac table.
6DoF treatment tables allow for 2 additional degrees (pitch and roll) compared to traditional 4DoF (vertical, lateral, longitudinal, and yaw) when correcting for patient setup during image-guidance prior to treatment delivery. These tables allow for more accurate patient treatments and could poten…
  • College: OSU Wexner Medical Center
  • Inventors: Woods, Kyle; Ayan, Ahmet; Gupta, Nilendu; Woollard, Jeffrey
  • Licensing Officer: Norris, Francis "Frank"

A novel STK1-targeted small molecule as an "antibiotic resistance breaker"
TS-037880 — Inh2-B1 serves as a therapeutically important “antibiotic-resistance-breaker,” which enhances the bactericidal activity of Ceftriaxone/Cefotaxime against highly pathogenic MDRSA infection.
Highly pathogenic and multidrug-resistant Staphylococcus species encompasses methicillin-resistant strains of S. aureus (MDRSA) and S. epidermidis (MDRSE) that have developed resistance to multiple traditional antibiotics, including the 5th generation cephalosporin (Ceftaroline). Because of the re…
  • College: College of Medicine (COM)
  • Inventors: Pancholi, Vijay
  • Licensing Officer: Davis, Stewart

Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
  • Licensing Officer: Taysavang, Panya

Novel Vaccine for Respiratory Syncytial Virus
TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.
Respiratory syncytial virus (RSV) is the most common cause of acute lower respiratory tract illness (ALRI) in infants, children, and the elderly, and often leads to fatal bronchiolitis and pneumonia. About 3.4 million children under the age of five are hospitalized each year due to an acute RSV in…
  • College: College of Veterinary Medicine
  • Inventors: Niewiesk, Stefan; Binjawadagi, Basavaraj; Li, Jianrong; Peeples, Mark
  • Licensing Officer: Dahlman, Jason "Jay"

Immunomodulating agents engineered from Notch receptor ligand extracellular domains
TS-036760 — Immunomodulating agents have been engineered from Notch receptor ligand extracelluar domains. These are useful for stimulating the immune system.
The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
  • College: College of Arts & Sciences
  • Inventors: Magliery, Thomas; Carbone, David; Dikov, Mikhail; Long, Nicholas; Sullivan, Brandon; Tchekneva, Elena
  • Licensing Officer: Willson, Christopher

Methods to Improve Mucosal Immune Response During Vaccination
TS-015239 — A method for enhancing the mucosal (IgA) immune response by transiently blocking a specific cellular subset during vaccination.
Mucosal IgA are immunoglobulins (antibodies) that play a key role in the defense of mucosal tissues by neutralizing pathogenic microorganisms and toxins and interfering with bacterial or viral colonization of the epithelium. An important component of needle-free vaccines is induction of mucosal Ig…
  • College: College of Veterinary Medicine
  • Inventors: Boyaka, Prosper
  • Licensing Officer: Dahlman, Jason "Jay"

Estrogen Receptor Beta Agonist Compounds
TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.
There is a large emphasis on the need for novel and more effective cancer therapeutics, since there were nearly 600,000 cancer deaths in the United States in 2016 alone. One method for therapy of prostate, breast, and colon cancer that has been gaining traction is the targeting of estrogen recepto…
  • College: College of Pharmacy
  • Inventors: Tjarks, Werner; Bartunek, Petr; Sedlak, David
  • Licensing Officer: Taysavang, Panya

Small Molecule AR-Ablative Agents
TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.
Hormone-refractory prostate cancer is incurable, and patients with this disease have few treatment options. Dysregulation of the androgen receptor (AR) is a hallmark of this incurable cancer. Molecular changes during cancer enhance AR sensitivity or permit AR activation by antiestrogen so that pro…
  • College: College of Pharmacy
  • Inventors: Chen, Ching-Shih; Wang, Dasheng; Yang, Jian
  • Licensing Officer: Taysavang, Panya

Show More Technologies

Loading icon